{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EVG%2FCOBI%2FFTC%2FTDF", "query": { "intervention": "EVG/COBI/FTC/TDF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EVG%2FCOBI%2FFTC%2FTDF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T07:18:25.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01533259", "title": "Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 9, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533259" }, { "nct_id": "NCT01495702", "title": "Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "NNRTI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 439, "start_date": "2011-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495702" }, { "nct_id": "NCT00042289", "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/cobicistat", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "elvitegravir/cobicistat", "type": "DRUG" }, { "name": "dolutegravir", "type": "DRUG" }, { "name": "tenofovir alafenamide fumarate (TAF)", "type": "DRUG" }, { "name": "TAF w/cobicistat", "type": "DRUG" }, { "name": "TAF w/cobicistat or ritonavir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "darunavir/cobicistat", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "atazanavir/ritonavir/tenofovir dosage #1", "type": "DRUG" }, { "name": "rifampicin", "type": "DRUG" }, { "name": "ethambutol", "type": "DRUG" }, { "name": "isoniazid", "type": "DRUG" }, { "name": "pyrazinamide", "type": "DRUG" }, { "name": "kanamycin", "type": "DRUG" }, { "name": "amikacin", "type": "DRUG" }, { "name": "capreomycin", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "levoflaxacin", "type": "DRUG" }, { "name": "ofloxacin", "type": "DRUG" }, { "name": "ethionamide/prothionamide", "type": "DRUG" }, { "name": "terizidone/cycloserine", "type": "DRUG" }, { "name": "para-aminosalicylic acid (PAS)", "type": "DRUG" }, { "name": "high dose INH", "type": "DRUG" }, { "name": "bedaquiline", "type": "DRUG" }, { "name": "clofazamine", "type": "DRUG" }, { "name": "delamanid", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "pretomanid", "type": "DRUG" }, { "name": "ethinyl estradiol", "type": "DRUG" }, { "name": "etonogestrel implant", "type": "DRUG" }, { "name": "nevirapine", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "fosamprenavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "didanosine delayed release (Videx® EC)", "type": "DRUG" }, { "name": "emtricitabine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "nelfinavir dosage #1", "type": "DRUG" }, { "name": "tipranavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #4", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" }, { "name": "maraviroc", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "tenofovir/atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "nelfinavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "rilpivirine", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1578, "start_date": "2003-06-09", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 39, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042289" }, { "nct_id": "NCT01721109", "title": "Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "EVG/COBI/FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 50, "start_date": "2012-12-06", "completion_date": "2018-01-29", "has_results": true, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 7, "location_summary": "Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721109" }, { "nct_id": "NCT03275701", "title": "Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Triumeq", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mills Clinical Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 50, "start_date": "2016-07", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2017-09-07", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275701" }, { "nct_id": "NCT00869557", "title": "Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-04", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 30, "location_summary": "Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869557" }, { "nct_id": "NCT02859558", "title": "Early ART to Limit Infection and Establishment of Reservoir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2017-01-24", "completion_date": "2025-04-16", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 23, "location_summary": "Birmingham, Alabama • San Diego, California • Torrance, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859558" }, { "nct_id": "NCT01095796", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "Atripla Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 707, "start_date": "2010-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095796" }, { "nct_id": "NCT01106586", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "ATV Placebo", "type": "DRUG" }, { "name": "RTV Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 708, "start_date": "2010-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 86, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Denver", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106586" }, { "nct_id": "NCT01815736", "title": "Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "EFV/FTC/TDF", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1443, "start_date": "2013-03-27", "completion_date": "2020-04-01", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-09-22T07:18:25.118Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815736" } ] }